33 clinical trials found.
-
A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER [Regeneron 5678-ONC-1879]
The purpose of the trial is to determine safety and tolerability of REGN5678 alone and in combination with cemiplimab in treatment-experienced metastatic castration-resistant prostate cancer ... -
A Phase 1 and 2a trial of LAVA-1207 in patients with therapy refractory metastatic castration resistant prostate cancer
The purpose of the study is to determine and investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary antitumor activity of LAVA-1207, a bi-specific antibody ... -
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumors and is testing a novel epigenetic modifying strategy to restore tumor cell differentiation.
The ...
-
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
This study wants to see if a new immunotherapy treatment called ONC-392, combined with Lu 177 vipivotide (Pluvicto) compared to Lu 177 vipivotide (Pluvicto) alone ...
-
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ... -
A Phase II Open Label Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1 / PD-L1 Based Immunotherapy
If you have been diagnosed with urothelial cancer that has progressed or returned, you may be qualified for this Phase 2 study. The main goal ... -
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
If you have been diagnosed with solid tumors, either removed previously by surgery or unresectable (locally advanced or metastatic), you may qualify for this phase ... -
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or ...
-
A Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination with a PARP Inhibitor in Patients with BRCA 1/2 Mutant or Other HRD+ Advanced or Metastatic S
This study is split into two parts: Phase 1 and Phase 2. The study team is testing a new medicine, TNG348, for patients with tumors ...
-
A Phase 2 Open-Label Multi-Center Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible fo
This study looks at two treatments (TAR-200 + IV cetrelimab versus IV cetrelimab alone) for a specific kind of bladder cancer (muscle-invasive bladder cancer unsuitable for ...